



## Europass Curriculum Vitae

### Personal information

First name / Surname **Andrea /Biondi**

Address

Telephone

Fax

E-mail

Nationality Italian

Date of birth

Gender Male

### Work experience

Dates October 2013 –October 2019

Occupation or position held Pro-Rector for International Affairs

Main activities and responsibilities Pro-Rector

Name and address of employer University of Milano-Bicocca, Milan, Italy

Type of business or sector Academic International Affairs

Dates November 2008 - onwards

Occupation or position held Director, Department of Paediatrics

Main activities and responsibilities Direction

Name and address of employer University of Milano-Bicocca, at Fondazione Monza e Brianza per il Bambino e la sua Mamma (FMBBM) Onlus/San Gerardo Hospital, Monza (MI), Italy

Type of business or sector Academic Hospital

Dates November 2008 - onwards

Occupation or position held Director, Residency Program in Pediatrics

Main activities and responsibilities Direction

Name and address of employer University of Milano-Bicocca, Milan, Italy

Type of business or sector Academic Hospital

Dates November 2007 - onwards

Occupation or position held PhD School of Translational and Molecular Medicine (DIMET) [www.dimet.org](http://www.dimet.org)

Main activities and responsibilities Direction

Name and address of employer University of Milano-Bicocca, Milan, Italy

Type of business or sector Academic

Dates Since 2006 - onwards

Occupation or position held Scientific Director

Main activities and responsibilities Direction

Name and address of employer Fondazione "M. Tettamanti & M. De Marchi" Onlus, Monza (MI), Italy

Type of business or sector Non-profit organization

Dates	Since 2006- onwards
Occupation or position held	Full professor of Pediatrics
Main activities and responsibilities	Educational and research activities
Name and address of employer	University of Milano-Bicocca, Milan, Italy
Type of business or sector	Academic
Dates	Since 2003 - onwards
Occupation or position held	Head
Main activities and responsibilities	Direction
Name and address of employer	"Stefano Verri" Cellular and Gene-TherapyLaboratory, Hospital S. Gerardo, Monza (MI) Italy
Type of business or sector	Laboratory
Dates	Since 1994 - onwards
Occupation or position held	Head
Main activities and responsibilities	Researches for leukemic and hematological diseases of children
Name and address of employer	"M.Tettamanti" Research Center, Hospital S. Gerardo, Monza (MI) Italy
Type of business or sector	Research Center
Dates	2008 - 2010
Occupation or position held	Coordinator, Master 1st Level of Pediatric Nursing
Main activities and responsibilities	Coordination
Name and address of employer	University of Milano-Bicocca, Milan, Italy
Type of business or sector	Academic
Dates	2006 - 2008
Occupation or position held	Coordinator, Master 1st Level of Palliative Cares
Main activities and responsibilities	Educational activities
Name and address of employer	University of Milano-Bicocca, Milan, Italy
Type of business or sector	Academic
Dates	2004 - 2008
Occupation or position held	Director, School of Oncology
Main activities and responsibilities	Educational activities
Name and address of employer	University of Milano-Bicocca, Milan, Italy
Type of business or sector	Academic
Dates	2000 - 2006
Occupation or position held	Associate professor of Pediatrics
Main activities and responsibilities	Educational and research activities
Name and address of employer	University of Milano-Bicocca, Milan, Italy
Type of business or sector	Academic
Dates	1999 - 2000
Occupation or position held	Assistant professor of Pediatrics
Main activities and responsibilities	Educational and research activities
Name and address of employer	University of Milano-Bicocca, Milan, Italy
Type of business or sector	Academic
Dates	1998 - 1999
Occupation or position held	Assistant professor of Pediatrics
Main activities and responsibilities	Educational and research activities
Name and address of employer	University of Milano, Milan, Italy
Type of business or sector	Academic

Dates	1987 - 1998
Occupation or position held	Physician staff
Main activities and responsibilities	Clinical and research activities
Name and address of employer	Dept. of Pediatrics, University of Milan, Hospital S.Gerardo Monza (MI) Italy
Type of business or sector	Academic hospital
<b>Education and training</b>	
Dates	1994
Title of qualification awarded	Specialist in Haematology
Principal subjects/occupational skills covered	Hematologic malignant and non-malignant diseases
Name and type of organisation providing education and training	University of Bari, Italy
Dates	1982
Title of qualification awarded	Specialist in Paediatrics
Principal subjects/occupational skills covered	Paediatrics
Name and type of organisation providing education and training	University of Milan, Italy
Dates	1979
Title of qualification awarded	M.D.
Principal subjects/occupational skills covered	License to practice medicine and surgery
Name and type of organisation providing education and training	University of Milan, School of Medicine, Italy
Dates	1986 - 1987
Title of qualification awarded	Research Associate in Medicine
Principal subjects/occupational skills covered	Research activities
Name and type of organisation providing education and training	Department of Bioresearch, The Ontario Cancer Institute, Toronto, Canada
Dates	1984 - 1986
Title of qualification awarded	Research Associate
Principal subjects/occupational skills covered	Research activities
Name and type of organisation providing education and training	Laboratory of Human Immunology "M.Negri" Institute, Milan, Italy
Dates	1982 - 1984
Title of qualification awarded	Research Associate in Pathology
Principal subjects/occupational skills covered	Research activities
Name and type of organisation providing education and training	Department of Tumor Immunology, Dana Farber Cancer Institute, Harvard Medical School, Boston, USA
Dates	1979 - 1982
Title of qualification awarded	Research fellow
Principal subjects/occupational skills covered	Research activities
Name and type of organisation providing education and training	Laboratory of Human Immunology "M.Negri" Institute, Milan, Italy



**Personal skills and competences**

Mother tongue(s) **Italian**

Other language(s)

Self-assessment

European level (\*)

**English**

**Spanish**

**French**

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
excellent	excellent	excellent	excellent	excellent
good	good	good	good	good
elementary	elementary	elementary	elementary	elementary

(\*) [Common European Framework of Reference for Languages](#)

Social skills and competences

2008-2011: Member of the Advisory Board of the UICC program "My Child Matters" (to reduce inequities in childhood cancer survival in low and mid-income countries).

1996-2004: Honorary Judge at the Juvenile Court of Milan.

1994-1998: National President of the Scout Association AGESCI

Organisational skills and competences

Since 1997 - onwards: Development and coordination of the "Monza International School of Pediatric Hematology/Oncology (MISPHO): a training program for medical and health personnel in the field of Pediatric Oncology, for countries with limited resources.

Since 1986- onwards: Development and coordination of a twinning program, for a Pediatric Oncology Project, with the Hospital "La Mascota" in Managua (Nicaragua) (see: Lancet 352.1923-6.1998).

Technical skills and competences

The training experience at the Harvard Medical School in Boston (1982-1984) and at the Ontario Cancer Institute in Toronto (1986-1987) were decisive in acquiring innovative technical skills that were transferred and further implemented in subsequent years.

Computer skills and competences

Skilled in the use of word, excel, power point and in the use of database and Internet.

Driving licence

Driving licence B

**Additional information**

Professional Societies

Since April 2016: Chairman of the International BFM Study Group (I-BFM-SG)

2012-2015: President of the Italian Association of Pediatric Hematology and Oncology (AIEOP)

2007-2011: Chairman of the EHA Nomination Committee

2004-2008: President of SIOP Europe

Since 2003: Organisation of the EHA-affiliated Paediatrics Haemato-Oncology courses held in the following years: 2003 (Spain), 2005 and 2007 (Sestri Levante, Italy), 2010 - 2011 - 2013 - 2015-2017 - 2019 (Sorrento, Italy)

2003: Chairman, Scientific Committee of the 8th Congress of the European Haematology Association (EHA)

2000-2004: Member of the European Haematology Association (EHA) Board

Since 1997: Member of the International Society of Pediatric Oncology (SIOP)

Since 1995: Member of the European Haematology Association (EHA)

Since 1992: Member of the Italian Society of Pediatric Hematology and Oncology (AIEOP)

Since 1992: Member of the American Society of Hematology (ASH)

Since 1991: Member of the Italian Society of Experimental Hematology

Since 1985: Member of the Italian Group of Cooperation in Immunology

Scientific Journals	<p>Member of the Editorial Board of Pediatric Blood &amp; Cancer, The European Journal of Cancer, HemaSphere, Pediatric Medicine</p> <p>Reviewer for: Annals of Oncology, Blood, British Journal of Haematology, The European Journal of Cancer, European Journal of Haematology, Genes Chromosomes and Cancer, Haematologica/The Hematology Journal, International Journal of Cancer, Leukemia</p>
Reviewer for funding programs and site visits of international organisations/agencies	<p>Cancer Research UK; Children Oncology Group, USA; Leukemia Research Fund, UK; National Cancer Institute/National Institute of Health, USA; OncoSuisse. Swiss Federation Against Cancer, CH; Stichting Kindergeneeskunde Kankeronderzoek (SKK), NL; International Union Against Cancer (UICC), CH; The French Society for Children Cancer and Leukemia (SFCE), F; KIKA Kinderenkankeervrij, NL; FWO, B.</p>
Major research interests	<ul style="list-style-type: none"> <li>- Molecular characterization of childhood ALL.</li> <li>- Minimal residual disease in childhood ALL.</li> <li>- Molecular characterization of the t(15;17) translocation in acute promyelocytic leukemia.</li> <li>- Molecular cloning of translocations.</li> <li>- Molecular and biological characterization of JMML.</li> <li>- Cellular and genetic manipulation of ALL blasts.</li> <li>- Development of strategies for immunotherapy of BCP-ALL;</li> <li>- Conduction of Clinical Trials under GCP conditions (GCP Training certificate on 05 Febr. 2016)</li> </ul>
Research Grants	<p>AIRC, 5x1000 - 22757 (2019-2026): "Disease-specific universal vaccines as new combinatorial immunotherapy for metastatic melanoma, sarcoma and osteosarcoma -MultiUnit"</p> <p>FRRB, CP2_10/2018 Plagencell (2019-2021): "A network for cell and gene therapies for devastating diseases"</p> <p>AIRC, 5x1000 - 21147 (2018-2025): "Immunity in Cancer Spreading and Metastasis (ISM) MultiUnit"</p> <p>AIRC, IG 2017 - 20564 (2018-2023): "Genomic profile and early response for improving cure rate and quality of life in childhood acute lymphoblastic leukemia"</p> <p>AIRC, Accelerator Award (2018-2023): "Innovative CAR Therapy Platforms (INCAR)"</p> <p>MIUR, PRIN 2018 (2018-2021): "Innovative approaches with genetically modified immune cells to target hematological malignancies"</p> <p>EU FP7, ERA NET TRANSCAN-2 (2018-2021): "Integration of genetic biomarkers and early minimal residual disease to improve risk stratification and cure in childhood Acute Lymphoblastic Leukemia Acronimo TRANSnational research in Childhood Acute Lymphoblastic Leukemia 2- TRANSCALL2 (ID 189)"</p> <p>InterReg, INTERREG-LEUCINI (2018-2020): "Collaborazione tra Enti di Ricerca, Piccola Media Impresa e Centri Ospedalieri per lo sviluppo di nuove terapie anti Leucemia basate su anticorpi e nanoparticelle"</p>
International references	<p>Mel F. Greaves, PhD  Professor of Cell Biology  Director  Leukemia Research Fund Centre  Institute of Cancer Research  Chester Beatty Laboratories  237 Fulham Road  London SW3 6JB, UK  e-mail: mel.greaves@icr.ac.uk</p> <p>Stephen Hunger, MD  Professor of Pediatrics  Department of Pediatrics and the Center for Childhood Cancer Research  The Children's Hospital of Philadelphia  3501 Civic Center Blvd  Philadelphia, PA, 19104  e-mail: HUNGERS@email.chop.edu</p>



Ching-Hon Pui, MD  
Director, Leukemia/Lymphoma Division  
St. Jude Children's Research Hospital  
and University of Tennessee Health Science Center  
332 N. Lauderdale St.  
Memphis, TN 38105, USA  
e-mail: Ching-Hon.Pui@stjude.org

## Annexes

### Selected papers

Tettamanti S, Pievani A, **Biondi A**, Dotti G, Serafini M. Catch me if you can: how AML and its niche escape immunotherapy. *Leukemia*. 2022 Jan;36(1):13-22. doi: 10.1038/s41375-021-01350-x. Epub 2021 Jul 23. PMID: 34302116; PMCID: PMC8727297.

Buchmann S, Schrappe M, Baruchel A, **Biondi A**, Borowitz MJ, Campbell M, Cario G, Cazzaniga G, Escherich G, Harrison CJ, Heyman M, Hunger SP, Kiss C, Liu HC, Locatelli F, Loh ML, Manabe A, Mann G, Pieters R, Pui CH, Rives S, Schmiegelow K, Silverman LB, Stary J, Vora A, Brown PA. Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium. *Blood*. 2021 Jun 30;blood.2021012328. doi: 10.1182/blood.2021012328. Epub ahead of print. PMID: 34192312.

den Boer ML, Cario G, Moorman AV, Boer JM, de Groot-Kruseman HA, Fiocco M, Escherich G, Imamura T, Yeoh A, Sutton R, Dalla-Pozza L, Kiyokawa N, Schrappe M, Roberts KG, Mullighan CG, Hunger SP, Vora A, Attarbaschi A, Zaliava M, Elitzur S, Cazzaniga G, **Biondi A**, Loh ML, Pieters R; Ponte di Legno Childhood ALL Working Group. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. *Lancet Haematol*. 2021;8(1):e55-e66. doi: 10.1016/S2352-3026(20)30353-7. Epub 2020 Dec 22. Erratum in: *Lancet Haematol*. 2021 Nov;8(11):e789. PMID: 33357483.

Cario G, Leoni V, Conter V, Baruchel A, Schrappe M, **Biondi A**. BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy. *Haematologica*. 2020 Sep 1;105(9):2200-2204. doi: 10.3324/haematol.2018.207019. PMID: 33054045; PMCID: PMC7556506.

Cario G, Leoni V, Conter V, Attarbaschi A, Zaliava M, Sramkova L, Cazzaniga G, Fazio G, Sutton R, Elitzur S, Izraeli S, Lauten M, Locatelli F, Basso G, Buldini B, Bergmann AK, Lentjes J, Steinemann D, Göhring G, Schlegelberger B, Haas OA, Schewe D, Buchmann S, Moericke A, White D, Revesz T, Stanulla M, Mann G, Bodmer N, Arad-Cohen N, Zuna J, Valsecchi MG, Zimmermann M, Schrappe M, **Biondi A**. Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. *Haematologica*. 2020 Jul;105(7):1887-1894. doi: 10.3324/haematol.2019.231720. Epub 2019 Oct 10. PMID: 31601692; PMCID: PMC7327633

Saetini F, Poli C, Vengoechea J, Bonanomi S, Orellana JC, Fazio G, Rodriguez FH, Noguera LP, Booth C, Jarur-Chamy V, Shams M, Iacone M, Vukic M, Gasperini S, Quadri M, Barroeta Seijas A, Rivers E, Mauri M, Badolato R, Cazzaniga G, Bugarin C, Gaipa G, Kroes WGM, Moratto D, van Oostaijen-Ten Dam MM, Baas F, van der Maarel S, Piazza R, Coban-Akdemir ZH, Lupski JR, Yuan B, Chinn IK, Daxinger L, **Biondi A**. Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency. *Blood*. 2021 Jan 28;137(4):493-499. doi: 10.1182/blood.202006441.

Pievani A, Donsante S, Tomasoni C, Corsi A, Dazzi F, **Biondi A**, Riminucci M, Serafini M. Acute myeloid leukemia shapes the bone marrow stromal niche in vivo. *Haematologica*. 2021 Mar 1;106(3):865-870. doi: 10.3324/haematol.2020.247205.

Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, Matera G, Cabiati B, Buracchi C, Borieri G, Fazio G, Zaninelli S, Tettamanti S, Cesana S, Colombo V, Quaroni M, Cazzaniga G, Rovelli A, Biagi E, Galimberti S, Calabria A, Benedicenti F, Montini E, Ferrari S, Introna M, Balduzzi A, Valsecchi MG, Dastoli G, Rambaldi A, **Biondi A**. Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. *J Clin Invest*. 2020 Nov 2;130(11):6021-6033. doi: 10.1172/JCI138473. PMID: 32780725; PMCID: PMC7598053.

Rotiroti MC, Buracchi C, Arcangeli S, Galimberti S, Valsecchi MG, Perriello VM, Rasko T, Alberti G, Magnani CF, Cappuzzello C, Lundberg F, Pande A, Dastoli G, Introna M, Serafini M, Biagi E, Izsvák Z, **Biondi A**, Tettamanti S. Targeting CD33 in Chemoresistant AML. Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System. *Mol Ther*. 2020 Sep 2;28(9):1974-1986. doi: 10.1016/j.ymthe.2020.05.021. Epub 2020 May 30. PMID: 32526203; PMCID: PMC7474266.



Santi L, De Ponti G, Dina G, Pievani A, Corsi A, Riminucci M, Khan S, Sawamoto K, Antolini L, Gregori S, Annoni A, **Biondi A**, Quattrini A, Tomatsu S, Serafini M. Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model. *Mol Genet Metab.* 2020 Jul;130(3):197-208. doi: 10.1016/j.ymgme.2020.05.001. Epub 2020 May 11.

Magnani CF, Tettamanti S, Alberti G, Pisani I, **Biondi A**, Serafini M, Gaipa G. Transposon-Based CAR T Cells in Acute Leukemias: Where are We Going? *Cells.* 2020 May 27;9(6):1337. doi: 10.3390/cells9061337

**Biondi A**, Cario G, De Lorenzo P, Castor A, Conter V, Leoni V, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Attarbaschi A, Li CK, Vora A, Bradtke J, Saha V, Valsecchi MG, Schrappe M. Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor. *Haematologica.* 2019;104(1):e13-e16.

Suttorp M, Metzler M, Millot F, Shimada H, Bansal D, Günes AM, Kalwak K, Sedlacek P, Baruchel A, **Biondi A**, Hijjiya N, Schultz KR, Schrappe M. Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients. *Pediatr Blood Cancer.* 2018;65(12):e27431.

Brown P, Pieters R, **Biondi A**. How I treat infant leukemia. *Blood.* 2019 Jan 17;133(3):205-214.

**Biondi A**, Gandemer V, De Lorenzo P, Cario G, Campbell M, Castor A, Pieters R, Baruchel A, Vora A, Leoni V, Stary J, Escherich G, Li CK, Cazzaniga G, Cavé H, Bradtke J, Conter V, Saha V, Schrappe M, Grazia Valsecchi M. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. *Lancet Haematol.* 2018 Dec;5(12):e641-e652.

Bardini M, Trentin L, Rizzo F, Vieri M, Savino AM, Garrido Castro P, Fazio G, Van Roon EHJ, Kerstjens M, Smithers N, Prinjha RK, TeKronnie G, Basso G, Stam RW, Pieters R, **Biondi A**, Cazzaniga G. Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4(+) Infant ALL. *Mol Cancer Ther.* 2018 Aug;17(8):1705-1716.

Pievani A, Michelozzi IM, Rambaldi B, Granata V, Corsi A, Dazzi F, **Biondi A**, Serafini M. Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice. *Sci Rep.* 2018 Jun 14;8(1):9125.

Magnani CF, Mezzanotte C, Cappuzzello C, Bardini M, Tettamanti S, Fazio G, Cooper LJJ, Dastoli G, Cazzaniga G, **Biondi A**, Biagi E. Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia. *Hum Gene Ther.* 2018. May;29(5):602-613.

Good Z, Sarno J, Jager A, Samusik N, Aghaeepour N, Simonds EF, White L, Lacayo NJ, Fantl WJ, Fazio G, Gaipa G, **Biondi A**, Tibshirani R, Bendall SC, Nolan GP, Davis KL. Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse. *Nat Med.* 2018. May;24(4):474-483.

Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen HO, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari GM, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt UZ, Aricò M, Conter V, Schrappe M, Valsecchi MG, **Biondi A**. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. *Haematologica.* 2018 Jan;103(1):107-115.

**Biondi A**, Magnani CF, Tettamanti S, Gaipa G, Biagi E. Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia. *J Autoimmun.* 2017 Dec;85:141-152.

## Publications (up to January 2022)

Nr. of publications on peer-review journals: 622  
H-index (Google Scholar): 117  
H-index (Scopus): 97  
Citations (Google Scholar): 56225  
Citations (Scopus): 38140

I authorize the processing of personal data in accordance with the provisions of art. 13 of Legislative Decree 196/03 and art. 13 GDPR 679/16.

Updated: January 2022 signature: .....

**Prof. Andrea Biondi**  
Direttore  
Clinica Pediatrica Università  
Milano Bicocca